Citius Oncology has secured up to $36.5m in a combination of debt and equity financing to accelerate the commercialisation of Lymphir (denileukin diftitox-cxdl), a recombinant fusion protein immune therapy.
Merck & Co (MSD) has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic myeloid leukaemia (CML).
Latus Bio has closed a $97m Series A financing round to expand the reach of its gene therapies to wider patient groups.
LEO Pharma has signed a definitive agreement for the acquisition of Replay, a gene therapy company that develops treatments for rare genetic dermatological conditions.
Ray Therapeutics has received priority medicines (PRIME) designation from the European Medicines Agency (EMA) for its RTx-015 gene therapy to treat retinitis pigmentosa (RP).
Arcera Life Sciences and Fosun Pharma have signed a memorandum of understanding (MoU) for a strategic long-term collaboration in licensing, technology, and neuroscience innovation in the global life sciences industry.
Rocket Pharmaceuticals has signed an agreement to sell its rare paediatric disease priority review voucher (PRV) for $180m to advance its gene therapy pipeline.
BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal for a total equity value of nearly $4.8bn.
Sun Pharmaceutical Industries has signed a definitive agreement to acquire Organon in a transaction with an enterprise valuation of $11.75bn in cash, paying $14.00 per share for all outstanding shares.
OZMOSI and Planview have formed a partnership to support pharmaceutical organisations by integrating Ozmosi’s structured, machine-readable clinical datasets with Planview’s AI-driven portfolio planning platform.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.